US-based molecular diagnostics company Mammogen has established a Leadership Council to support the clinical development, adoption and accessibility of its emerging breast cancer detection technology, bringing together healthcare industry experts and breast cancer survivors to help shape its strategy.
Announced on 17 November 2026, the initiative represents an effort to connect scientific research with clinical practice and patient experience as Mammogen advances its blood-based RNA diagnostic technology through clinical validation.
The company has appointed Dr Yuri Fesko, former Chief Medical Officer of Quest Diagnostics and current Chief Medical Officer of Quanterix, as the council’s founding member.
Unlike a conventional scientific advisory board, the Leadership Council is designed to bring together expertise from clinical medicine, laboratory diagnostics, healthcare delivery and commercial strategy, alongside the perspectives of women who have experienced breast cancer.
The council will focus on helping Mammogen develop the partnerships, clinical pathways and operational strategies required to bring emerging diagnostic technology into healthcare settings.
Under the leadership of Chief Executive Officer Elizabeth Cormier-May, Mammogen is developing genTRU-breast™, a blood-based RNA diagnostic intended to complement conventional breast imaging.
The technology is being investigated for its ability to identify biological signals associated with breast cancer, potentially providing additional information to support clinical decision-making.
Mammogen’s approach focuses particularly on women with dense breast tissue, for whom conventional imaging may present additional challenges.
However, the technology remains under clinical validation and has not yet established its effectiveness for routine clinical use.
The company is currently conducting its KATELYN-ERIN prospective clinical study, which is intended to generate evidence supporting the further development of genTRU-breast.
The establishment of the Leadership Council comes as Mammogen seeks to translate its scientific research into a diagnostic approach that could eventually be integrated into existing breast healthcare pathways.
Cormier-May has emphasised that scientific innovation alone is insufficient to change how healthcare is delivered.
She explained that successful adoption of new diagnostic technologies requires clinical confidence, commercial execution, healthcare system engagement and meaningful input from the patients who may ultimately benefit.
The council has therefore been structured to involve individuals with experience across multiple aspects of healthcare, rather than relying exclusively on scientific or medical expertise.
Its founding member, Dr Fesko, brings experience in clinical oncology, precision medicine and laboratory diagnostics.
Before joining Quanterix, he served as Chief Medical Officer of Quest Diagnostics, one of the largest diagnostic testing organisations in the United States.
During his tenure at Quest, Fesko contributed to molecular oncology and precision medicine initiatives, including the development of comprehensive tumour sequencing capabilities and the integration of advanced diagnostic technologies into clinical practice.
His background as a practising oncologist and senior healthcare executive is expected to support Mammogen’s efforts to understand the requirements involved in introducing new diagnostic tools into routine medical practice.
Fesko has highlighted the importance of demonstrating clinical value and securing physician confidence before emerging technologies can achieve widespread adoption.
He also identified the integration of molecular diagnostics with existing breast imaging procedures as an important area for further investigation.
Alongside industry and clinical expertise, Mammogen intends to involve breast cancer survivors and patient representatives in the council’s strategic discussions.
Their participation will provide perspectives on diagnostic uncertainty, communication with healthcare professionals, treatment-related decisions and barriers to accessing care.
For women undergoing breast cancer investigations, the period between an initial screening result and a definitive diagnosis can involve significant uncertainty.
The company believes that including patient experiences in discussions about diagnostic development could help ensure that future technologies respond to practical needs within the healthcare system.
DeeDee DeMan, Chairwoman of Mammogen’s Board of Directors and Founder, Chair and CEO of Bench International, has also supported the inclusion of survivors and advocates in the council.
She emphasised that individuals with direct experience of healthcare challenges can provide insights that may not emerge through scientific or commercial evaluation alone.
By involving these perspectives, Mammogen aims to strengthen the relationship between diagnostic innovation and the needs of the women it intends to serve.
The Leadership Council will operate under the guiding philosophy of bringing together different perspectives around the shared objective of obtaining earlier answers in breast healthcare.
The initiative also reflects Mammogen’s wider approach to women’s health diagnostics.
The company is developing RNA-based molecular technologies intended to identify biological signals associated with disease.
Its platform combines RNA biomarker discovery with computational analysis, with breast cancer representing its initial area of focus.
The company has indicated that the underlying technology could eventually support additional applications across women’s healthcare.
However, these potential applications remain dependent on further research, clinical validation and applicable regulatory requirements.
Mammogen’s latest announcement comes amid growing interest in diagnostic technologies that may complement existing screening methods and provide additional biological information.
While mammography and other imaging techniques remain central to breast cancer detection, researchers continue to investigate whether molecular diagnostics can offer useful supplementary insights.
Blood-based tests are among the approaches being studied, although their clinical performance and appropriate role in screening or diagnosis must be established through rigorous evidence.
For Mammogen, the immediate priority is advancing genTRU-breast through prospective clinical validation while developing the relationships necessary for potential future adoption.
The Leadership Council is intended to support that process by connecting scientific development with clinical expertise, healthcare operations, commercial partnerships and patient advocacy.
The appointment of Fesko represents the first step in establishing the council, with additional members expected to contribute expertise from across the healthcare sector.
For Cormier-May, the initiative reflects a broader approach to leadership in women’s healthcare innovation, one that considers not only the development of new technologies but also how those technologies may eventually reach patients.
By including breast cancer survivors in strategic discussions alongside healthcare executives and medical professionals, Mammogen is seeking to make patient experience an integral part of its diagnostic development strategy.
The council’s longer-term impact will depend on its contribution to clinical validation, healthcare partnerships and the eventual accessibility of the company’s technology.
